Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vivani Medical, Inc.EYES · Entity 6636 | VP-Clin & Scientific Affairs | February 12, 2020 | February 14, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vivani Medical, Inc.
Report date February 12, 2020 · Filed February 14, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option(right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.98 · Expires 2030-02-12 | Direct | 8,899 |
Reported balance
After 2020-02-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-12 · Grant · Acquired 8,899 · Balance 8,899 F1: The stock options have a 10-year term and vest over four years from the grant date in equal monthly installments, subject to continuous employment, such that the total number shall be fully vested on the four-year anniversary of the transaction date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options have a 10-year term and vest over four years from the grant date in equal monthly installments, subject to continuous employment, such that the total number shall be fully vested on the four-year anniversary of the transaction date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2020 Filed Feb 14, 2020 19:17 UTC | Vivani Medical, Inc. EYES · Entity 6636 | GrantNon-Qualified Stock Option(right to buy) · Derivative | 8,899 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001209191-20-009542 · doc4.xml · derivative · entry 1 Dorn Jessy Dana · CIK 0001789796 · VP-Clin & Scientific Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,899 Underlying: Common Stock · 8,899 shares Expires 2030-02-12 F1 · derivative.exercise_date: The stock options have a 10-year term and vest over four years from the grant date in equal monthly installments, subject to continuous employment, such that the total number shall be fully vested on the four-year anniversary of the transaction date. Read SEC document |
| December 03, 2019 Filed Dec 4, 2019 23:09 UTC | Vivani Medical, Inc. EYES · Entity 6636 | Disposition to issuerCommon Stock | 7,265 | $0.81 | $5,891.92 |
DisclosureSEC source: 0001209191-19-059148 · doc4.xml · nonDerivative · entry 2 Dorn Jessy Dana · CIK 0001789796 · VP-Clin & Scientific Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,458 Read SEC document |
| November 29, 2019 Filed Dec 4, 2019 23:09 UTC | Vivani Medical, Inc. EYES · Entity 6636 | GrantCommon Stock | 7,265 | $0.59 | $4,315.41 |
DisclosureSEC source: 0001209191-19-059148 · doc4.xml · nonDerivative · entry 1 Dorn Jessy Dana · CIK 0001789796 · VP-Clin & Scientific Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,723 F1 · shares: Shares acquired under the 2015 Employee Stock Purchase Plan (ESPP). The sale of these shares was executed pursuant to an election made on 11/25/2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.